Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + carfilzomib + dexamethasone in relapsed or refractory multiple myeloma
2023-505659-27-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of venetoclax, carfilzomib and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability, Safety and preliminary efficacy by venetoclax dose level versus Kd control and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
venetoclaxcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-505659-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505659-27-00.